With full commercial marijuana in the United States years away, there is plenty of time to place your bets on the cannabis sector. With the market overvalued, it may pay to wait things out until a screaming buy emerges. This is especially the case with Cronos. While the company may see parabolic growth in the next few years, much of this is reflected in the current share price. The partnership with Altria gives the company a solid strategic partner. But the highly dilutive nature of the deal minimizes potential upside.